Stryker's Q4, 2012 Earnings Slide

Stryker (NYSE: SYK  ) saw a fairly steep year-over-year decline of 33% in net profit for its Q4, according to a company release announcing quarterly and fiscal 2012 results. The bottom line came in at $270 million (diluted $0.71 per share), well short of the $401 million ($1.05 diluted EPS) it posted in the same quarter of 2011. Net sales, meanwhile, grew 6% on an annual basis to $2.3 billion.

Much of the net profit shortfall was due to a $133 million charge the company took for the recall of a pair of modular-neck hip stem products, the Rejuvenate and the ABG II.

For the full year, the company's net sales advanced 4% over those of 2011 to land at $8.7 billion. Net profit dropped 4% to $1.3 billion ($3.39 diluted EPS).

Looking forward, the firm expects sales to grow 3%-5.5% on a constant currency basis. It's currently modeling EPS of $4.25-$4.40.

Earlier this month, Stryker announced that it made a $764 million offer to acquire Hong Kong-listed Trauson Holdings, a maker of goods for patients with spinal difficulties. The company anticipates that the purchase will not significantly affect earnings for this year.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2211779, ~/Articles/ArticleHandler.aspx, 4/18/2014 5:29:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement